FDA decision on Chelsea's Northera expected in March 2012
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics stock got a 6.6% boost on 17 November after the firm said the US FDA had accepted for filing the Charlotte, North Carolina-based company's new drug application for Northera (droxidopa) as a treatment for symptomatic neurogenic orthostatic hypotension (NOH), a chronic neurogenic disorder resulting from deficient release of norepinephrine, the neurotransmitter used by autonomic nerves to send signals to the blood vessels and the heart.